CBT

CBT Change in Working Capital

-$22.00MTTM · USD

Period ending:

CBT FY Change in Working CapitalUSD
CBT FY Change in Working Capital1989-09-30: -$62.30M1990-09-30: $8.80M1991-09-30: -$4.80M1992-09-30: -$64.20M1993-09-30: $38.70M1994-09-30: -$44.60M1995-09-30: -$102.30M1996-09-30: -$42.30M1997-09-30: -$62.60M1998-09-30: $15.50M1999-09-30: -$41.00M2000-09-30: -$56.00M2001-09-30: -$254.00M2002-09-30: -$58.00M2003-09-30: $26.00M2004-09-30: -$64.00M2005-09-30: -$63.00M2006-09-30: -$6.00M2007-09-30: $26.00M2008-09-30: -$124.00M2009-09-30: $321.00M2010-09-30: -$84.00M2011-09-30: -$192.00M2012-09-30: $39.00M2013-09-30: $47.00M2014-09-30: -$153.00M2015-09-30: $102.00M2016-09-30: $45.00M2017-09-30: -$51.00M2018-09-30: -$129.00M2019-09-30: $18.00M2020-09-30: $162.00M2021-09-30: -$244.00M2022-09-30: -$448.00M2023-09-30: $100.00M2024-09-30: $70.00M2025-09-30: $49.00M$321.00M-$448.00M
1989-09-302025-09-30

Source: Financial Modeling Prep (FMP). Annual fiscal periods; reported in USD. Dates are period ends; a fiscal year may differ from a calendar year.

CBT change in working capital history

Working capital impact on cash flow. The available annual fiscal periods series contains 37 observations from Sep 30, 1989 to Sep 30, 2025.

Cabot Corp Change in Working Capital — Annual fiscal periods (USD)
Period endingChange in Working Capital (USD)
49,000,000
70,000,000
100,000,000
-448,000,000
-244,000,000
162,000,000
18,000,000
-129,000,000
-51,000,000
45,000,000
102,000,000
-153,000,000
47,000,000
39,000,000
-192,000,000
-84,000,000
321,000,000
-124,000,000
26,000,000
-6,000,000
-63,000,000
-64,000,000
26,000,000
-58,000,000
-254,000,000
-56,000,000
-41,000,000
15,500,000
-62,600,000
-42,300,000
-102,300,000
-44,600,000
38,700,000
-64,200,000
-4,800,000
8,800,000
-62,300,000

Compare change in working capital

All CBT financial metrics · CBT stock overview · How to interpret financial metrics

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.